Safety and dose-finding study of activated protein c (drotrecogin alfa activated) as an anticoagulant in end-stage renal disease patients treated with hemodialysis

Blood Purification

Volumn 37, Issue 3, 2014, Pages 243-248

  Brasha Mitchell, Ermira ^a   Collins, Ashte ^b   Shehu, Lindita ^a   Seneff, Michael G ^a   Patel, Samir S ^b   Chawla, Lakhmir S ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN; LABETALOL;

BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; RENAL REPLACEMENT THERAPY; ADULT; AFRICAN AMERICAN; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; END STAGE RENAL DISEASE; HEMODIALYSIS; HYPERTENSION; MEDICAL HISTORY; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 84902909280     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000362154     Document Type: Article

References (12)

1. Collins AJ, Foley RN, Gilbertson DT, Chen SC: The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009; 4(suppl 1):S5-S11.
2. Kaysen GA: Role of inflammation and its treatment in ESRD patients. Blood Purif 2002; 20:70-80. (Pubitemid 34102511)
3. Kimmel PL, Phillips TM, Simmens SJ, et al: Immunologic function and survival in hemo-dialysis patients. Kidney Int 1998; 54:236-244. (Pubitemid 28288040)
4. Bologa RM, Levine DM, Parker TS, et al: In-terleukin-6 predicts hypoalbuminemia, hy-pocholesterolemia, and mortality in hemodi-alysis patients. Am J Kidney Dis 1998; 32:107-114. (Pubitemid 28311878)
5. Goldstein SL, Leung JC, Silverstein DM: Pro-and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 2006; 1:979-986.
6. Toltl LJ, Austin RC, Liaw PC: Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. J Thromb Hae-most 2011; 9:582-592.
7. Topal E, Ozturk E, Sen G, Yerci O, Yilmazlar T: A comparison of three fibrinolytic agents in prevention of intra-abdominal adhesions. Acta Chir Belg 2010; 110:71-75.
8. Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007; 11(suppl 5):S3.
9. Vincent JL: Drotrecogin alpha (activated): the treatment for severe sepsis? Expert Opin Biol Ther 2007; 7:1763-1777.
10. Sun HM, Hong LZ, Shen XK, Lin XQ, Song Y, Shi Y: Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. Chin Med J (Engl) 2009; 122:2466-2471.
11. Schirm S, Liu X, Jennings LL, Jedrzejewski P, Dai Y, Hardy S: Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-termi-nal peptides eliminate serum-resistant Esch-erichia coli from blood cultures. J Infect Dis 2009; 199:1807-1815.
12. Morser J: Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets 2012; 13:421-431.